Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Предоперационная (неоадъювантная) эндокринотерапия постменопаузальных больных раком молочной железы
Предоперационная (неоадъювантная) эндокринотерапия постменопаузальных больных раком молочной железы
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Семиглазов В.Ф., Семиглазов В.В., Клетсель А.Е. Неоадъювантное и адъювантное лечение рака молочной железы. М.: МИА, 2008.
2. Семиглазов В.Ф., Семиглазов В.В., Клетсель А.Е. Неинвазивные и инвазивные опухоли молочной железы. М.: Боргес, 2006.
3. Howel A, Cuzick J, Baum M et al. Results of the ANAC trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.
4. Abriel C, Mouret-Reynier M, Cure H et al. Neoadjuvant endocrine therapy in breast cancer. The Breast 2006; 15: 9–19.
5. Gazet J, Coombes R, Ford H et al. Assessment of the effect of pretreatment with neoadjuvant therapy of primary breast cancer. Brit J Cancer 1996; 73: 758–62.
6. Mauriac L, Debled M, MacGrogan G. When will more useful predictive factors be ready for use? The Breast 2005; 14: 617–23.
7. Dixon J, Anderson T, Miller W. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer 2002; 38: 2214–21.
8. Dixon J, Renshaw L, Blamy D et al. Arimidex as neoadjuvant therapy causes large reductions in tumor volume in postmenopausal women with large operable breast cancer. Proc ASCO meeting. Atlanta-1999; 345: 92a.
9. Dixon J, Bundred N. Aromatase inhibitors for early breast cancer therapy: a choice of effective treatment strategies. Eur J Surg Oncol 2006; 32: 123–5.
10. Smith I, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2006; 348: 2431–42.
11. Cataliotti L, Buzdar A, Noguchi S et al. The preoperative «arimidex» compared to tamoxifen (PROACT). Trial Cancer 2006; 106: 2095–103.
12. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12: 1527–32.
13. Gianni L, Baselga J, Eiermann W et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexat and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005; 11: 8715–21.
14. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808–16.
15. Semiglazov VF, Semiglazov VV, Ivanov V et al. The relative efficacy of neoadjuvant endocrine therapy vs. chemotherapy in postmenopausal women with ER-positive breast cancer. J Clin Oncol 2004; 22: 519.
16. Semiglazov VF, Semiglazov VV, Dashyan G et al. Randomized trial of primary edocrine terapy versus chemotherapy in postmenopausal patients with estrogen receptor positive breast cancer. Cancer 2007; 110: 244–54.
17. Semiglazov VF, Dashyan G, Semiglazov VV et al. Primary endocrine therapy versus chemotherapy in postmenopausal patients with ER-positive breast cancer: 5 year results. Breast-2009; 18 (suppl.): 63.
2. Семиглазов В.Ф., Семиглазов В.В., Клетсель А.Е. Неинвазивные и инвазивные опухоли молочной железы. М.: Боргес, 2006.
3. Howel A, Cuzick J, Baum M et al. Results of the ANAC trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.
4. Abriel C, Mouret-Reynier M, Cure H et al. Neoadjuvant endocrine therapy in breast cancer. The Breast 2006; 15: 9–19.
5. Gazet J, Coombes R, Ford H et al. Assessment of the effect of pretreatment with neoadjuvant therapy of primary breast cancer. Brit J Cancer 1996; 73: 758–62.
6. Mauriac L, Debled M, MacGrogan G. When will more useful predictive factors be ready for use? The Breast 2005; 14: 617–23.
7. Dixon J, Anderson T, Miller W. Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer 2002; 38: 2214–21.
8. Dixon J, Renshaw L, Blamy D et al. Arimidex as neoadjuvant therapy causes large reductions in tumor volume in postmenopausal women with large operable breast cancer. Proc ASCO meeting. Atlanta-1999; 345: 92a.
9. Dixon J, Bundred N. Aromatase inhibitors for early breast cancer therapy: a choice of effective treatment strategies. Eur J Surg Oncol 2006; 32: 123–5.
10. Smith I, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2006; 348: 2431–42.
11. Cataliotti L, Buzdar A, Noguchi S et al. The preoperative «arimidex» compared to tamoxifen (PROACT). Trial Cancer 2006; 106: 2095–103.
12. Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001; 12: 1527–32.
13. Gianni L, Baselga J, Eiermann W et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexat and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005; 11: 8715–21.
14. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808–16.
15. Semiglazov VF, Semiglazov VV, Ivanov V et al. The relative efficacy of neoadjuvant endocrine therapy vs. chemotherapy in postmenopausal women with ER-positive breast cancer. J Clin Oncol 2004; 22: 519.
16. Semiglazov VF, Semiglazov VV, Dashyan G et al. Randomized trial of primary edocrine terapy versus chemotherapy in postmenopausal patients with estrogen receptor positive breast cancer. Cancer 2007; 110: 244–54.
17. Semiglazov VF, Dashyan G, Semiglazov VV et al. Primary endocrine therapy versus chemotherapy in postmenopausal patients with ER-positive breast cancer: 5 year results. Breast-2009; 18 (suppl.): 63.
Авторы
В.Ф.Семиглазов1, В.В.Семиглазов2, Е.К.Жильцова1
1 ФГУ НИИ онкологии им. Н.Н.Петрова Росмедтехнологий,
2 Санкт-Петербургский государственный медицинский университет им. И.П.Павлова
1 ФГУ НИИ онкологии им. Н.Н.Петрова Росмедтехнологий,
2 Санкт-Петербургский государственный медицинский университет им. И.П.Павлова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.